- 著者
- Kimihiro Okubo Satoshi Ogino Toshikazu Nagakura Takeru Ishikawa
- 出版者
- Japanese Society of Allergology
- 雑誌
- Allergology International (ISSN:13238930)
- 巻号頁・発行日
- vol.55, no.4, pp.379-386, 2006 (Released:2006-12-18)
- 参考文献数
- 25
- 被引用文献数
- 79
Background: Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollen is a substantial problem in Japan. Omalizumab, a novel humanized monoclonal anti-immunoglobulin E (IgE) antibody, has already been proven to reduce symptoms associated with SAR. We investigated the safety and efficacy of omalizumab in the treatment of patients with Japanese cedar pollen-induced SAR compared to placebo. Methods: A randomized, placebo-controlled, double-blind study was conducted in 100 Japanese patients with a history of moderate-to-severe SAR induced by Japanese cedar pollens. Omalizumab (150, 225, 300, or 375mg) or placebo was administered subcutaneously every 2 or 4 weeks based on serum total IgE and body weight at baseline. The primary efficacy variable was the mean of daily nasal symptom medication scores (sum of the daily nasal symptom severity score and daily nasal rescue medication score) during the treatment period. Secondary efficacy variables included the daily ocular symptom medication score and related variables. Results: Primary and all secondary efficacy variable scores were significantly lower in the omalizumab group than in the placebo group (P Conclusions: Omalizumab was effective and safe in the treatment of SAR induced by Japanese cedar pollen.
- 著者
- Minoru Okuda Atsushi Usami Hirotaka Itoh Satoshi Ogino
- 出版者
- The Oto-Rhino-Laryngological Society of Japan, Inc.
- 雑誌
- Nippon Jibiinkoka Gakkai Kaiho (ISSN:00306622)
- 巻号頁・発行日
- vol.105, no.12, pp.1181-1188, 2002-12-20 (Released:2008-03-19)
- 参考文献数
- 29
- 被引用文献数
- 4 7
アレルギー性鼻炎患者(AR)における昆虫アレルゲンの症状への関与を調べるため,560例のARを対象にしてガ,ユスリカ,ゴキブリを含む13アレルゲンに対するIgE抗体を測定した.また,65例の患者でこれら3種の昆虫の鼻誘発試験を実施した.ガ,ユスリカおよびゴキブリに対するIgE抗体保有率はそれぞれ32.5%,16.1%,13.4%であった.これらIgE抗体保有率には,地域,年齢,治療および合併症による差は認められなかった.鼻誘発試験で陽性と判定される割合は,RASTクラスが高いほど多くなる傾向があった.とくにゴキブリ,ガにおいて,RASTクラス3以上では,各々55.6%および61.5%が鼻誘発試験に陽性を示した.昆虫間のIgE抗体価の相関を検討したところ,ガ,ユスリカ間には強い相関が認められ共通抗原性を示唆したが,ゴキブリ,ガ間およびゴキブリ,ユスリカ間では強い相関は認められなかった.また,いずれの昆虫もヤケヒョウヒダニおよび室内塵に対するIgE抗体価との相関は認めなかった.以上の結果,日本においてガ,ユスリカ,ゴキブリは,アレルギー性鼻炎を起こす原因となっていることが示された.
- 著者
- Syuji Yonekura Yoshitaka Okamoto Daiju Sakurai Toshioki Sakurai Tomohisa Iinuma Heizaburou Yamamoto Toyoyuki Hanazawa Shigetoshi Horiguchi Yuichi Kurono Kohei Honda Yuichi Majima Keisuke Masuyama Noriaki Takeda Shigeharu Fujieda Mitsuhiro Okano Satoshi Ogino Kimihiro Okubo
- 出版者
- 一般社団法人日本アレルギー学会
- 雑誌
- Allergology International (ISSN:13238930)
- 巻号頁・発行日
- vol.66, no.3, pp.425-431, 2017 (Released:2017-07-25)
- 参考文献数
- 38
- 被引用文献数
- 13
Background: Complementary and alternative medicine (CAM) is extensively used in patients with allergic diseases worldwide. The purpose of this study was to investigate the actual situation of CAM practice in the treatment of allergic rhinitis.Methods: We distributed questionnaires to otolaryngologists at 114 facilities in Japan. The subjects who participated in this study included children <16 years of age and adults ≥16 years of age diagnosed with allergic rhinitis by otolaryngologists. The survey was performed in the period from September 2007 to August 2009. Furthermore, we performed the same investigation out of the hospital setting, such as during general health examinations. All questionnaires were returned to Chiba University and analyzed.Results: The proportions of patients who had ever experimented with CAM in the hospital survey were 7.1% (225/3170) and 19.2% (1416/7363) of children and adults, respectively. Approximately 36.2% of the adult patients thought that the treatments were effective. The main reasons for CAM use were safety, convenience and low price. However, the group who spent more than $1000 on CAM felt more dissatisfaction and anxiety related to treatment at the hospital. The situation of CAM practice was not consistent and was instead influenced by the backgrounds of the subjects.Conclusions: Many patients who receive CAM report feeling that the effects of treatment provided by hospitals are insufficient and have concerns about the side effects of such treatments. Information regarding standard treatments, as described in the guidelines, should become widely known and diffused, and strong communication with patients should be considered.